Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Ghatalia, Pooja; Je, Youjin; Mouallem, Nemer El; Nguyen, Paul L.; Trinh, Quoc-Dien; Sonpavde, Guru; Choueiri, Toni K.
• Is Part Of: Critical reviews in oncology/hematology. Volume 93:Issue 3(2015)
• Page Start: 257
• Page End: 276
• Publication Date: 2015-03
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2014.11.006
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <p id="spar0005">A meta-analysis of randomized controlled trials (RCT) was conducted to determine the relative risk (RR) of hepatotoxicity with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Citations from PubMed/Medline, abstracts from major conferences, clinicaltrials.gov and package inserts were reviewed to include RCTs comparing arms with or without a VEGFR TKI. The RRs of all-grade ALT, AST, ALP and bilirubin elevation in 18, 282 patients from 52 trials were 1.57 (95% CI 1.38–1.79, <italic>p</italic> &lt; 0.001), 1.57 (95% CI 1.36–1.81, <italic>p</italic> &lt; 0.001), 1.20 (95% CI 1.09–1.83, <italic>p</italic> &lt; 0.001) and 1.55 (95% CI 1.21–1.97, <italic>p</italic> &lt; 0.001) respectively, and high-grade elevations were 1.66 (95% CI 1.25–2.20, <italic>p</italic> = 0.001), 1.61 (95% CI 1.21–2.14, <italic>p</italic> = 0.001), 1.02 (95% CI 0.70–1.47, <italic>p</italic> = 0.932) and 1.34 (95% CI 1.0–1.81, <italic>p</italic> = 0.054) respectively compared to those in the non-TKI group. The incidence of hepatic failure with VEGFR TKIs was 0.8%.</p> </sec> </abstract>